Schedule of Events

View the disclosures of all presenters (potential conflicts of interests have been reviewed and managed).

[M] = medical oncologist, [R] = radiation oncologist, [S] = surgeon/surgical oncologist

Wednesday, February 26, 2020

Thursday, February 27, 2020

7:00 a.m. - 4:15 p.m.	Registration
7:00 a.m. - 8:00 a.m.	Continental Breakfast
7:55 a.m. - 8:00 a.m.	Day One Welcome Quynh-Thu Le, MD, FASTRO, Stanford University, Stanford, California [R]
8:00 a.m. - 9:30 a.m.	Oral Cavity Moderator: Maie St. John, MD, PhD, UCLA Medical Center, Los Angeles [S] Guidelines for Oral Cavity - Maie St. John, MD, PhD, UCLA Medical Center, Los Angeles [S] Surgical Perspectives on Oral Cavity Squamous Cell Carcinoma - Nishant Agrawal, MD, University of Chicago, Chicago [S] Radiation Oncology for Oral Cavity Carcinoma - Beth Beadle, MD, PhD, Stanford University, Stanford, California [R] Systemic Therapy for Oral Cavity Cancer - Tanguy Seiwert, MD, Johns Hopkins University, Baltimore [M] Questions and Answers
9:30 a.m. - 10:15 a.m.	Keynote I: Cutting-edge Combinations with Radiation Moderator: Sue Yom, MD, PhD, University of California, San Francisco [R] Speaker: Jean Bourhis, MD, PhD, Universite de Lausanne, Lausanne, Switzerland [R]
10:15 a.m. - 10:45 a.m.	Coffee Break
10:45 a.m. - 12:15 p.m.	K. Kian Ang, MD, PhD, FASTRO, Commemorative Plenary Session Moderator: Tanguy Y. Seiwert, MD, Johns Hopkins University, Baltimore [M] 1: Neoadjuvant Nivolumab +/- Ipilimumab in Patients with Oral Cavity Cancer - Jonathan Schoenfeld, MD, MPH, Brigham and Women's Hospital, Boston 2: Immune Modulation in a Randomized Trial of Neoadjuvant IRX-2 Regimen in Patients with Stage II-IV Squamous Cell Carcinoma (SCC) of the Oral Cavity - INSPIRE Trial (NCT 02609386) Interim Analysis - Gregory Wolf, MD, University of Michigan, Ann Arbor, Michigan 3: Spatial evolution of lymph node metastasis in Human Papillomavirus-negative Head and Neck Cancers - Michael Spiotto, MD, PhD, University of Chicago, Chicago 4: Exploration of Next-Generation Sequencing of Tumor Tissue and Blood in Head and Neck Squamous Cell Carcinoma - Mercedes Porosnicu, MD, Wake Forest University School of Medicine, Winston Salem, North Carolina 5: Multi-Institutional Randomized Double-Blind Phase II Trial of Everolimus vs. Placebo as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN) - Cherie-Ann O. Nathan, MD, Louisiana State University Health Sciences Center, Shreveport, Louisiana 6: Long-Term Update of NRG Oncology RTOG 0522: A Randomized Phase III Trial of Concurrent Radiation and Cisplatin with or without Cetuximab in Locoregionally Advanced Head and Neck Cancer - Jimmy J. Caudell, MD, PhD, Moffitt Cancer Center, Tampa, Florida 7: Clinical Outcomes and Toxicity Profile with IMRT or Brachytherapy Boost in Oropharyngeal Malignancies: A Randomized, Open Label Study - Vibhay Pareek, MD, All India Institute of Medical Sciences, New Delhi, India 8: Risk of Suicidal Self-directed Violence Among Survivors of Head and Neck Cancer: A Retrospective Cohort Analysis - Shannon Nugent, PhD, VA Portland Health Care System, Portland, Oregon 9: Distress Screening and Follow-Up Among Patients Within a Multidisciplinary Head and Neck Cancer Program - Stephanie Lazaro, University of California, Los Angeles, Los Angeles
12:15 p.m. - 1:15 p.m.	Lunch in the Exhibit Hall Expert Office Hour During the Expert Office Hour, attendees can join informal round tables where two experts will be available for attendees to converse about whatever the group would like to discuss (it could be anything from career advice to discussion about a challenging case). No sign-up in advance is required. Experts: June Corry, MD, MBBS, FRACP, FRANZCR, St. Vincent’s Melbourne, Australia [R] Quynh-Thu Le, MD, FASTRO, Stanford University, Stanford, California [R] Douglas R. Adkins, MD, Washington University School of Medicine, St. Louis [M] Jill Gilbert, MD, FACP, FASCO, Vanderbilt University Medical Center, Nashville, Tennessee [M] Nishant Agrawal, MD, University of Chicago, Chicago [S] Cherie-Ann O. Nathan, MD, Louisiana State University Health Sciences Center, Shreveport, Louisiana [S]
1:15 p.m. - 2:45 p.m.	HPV-associated Oropharyngeal Squamous Cell Carcinoma Moderator: David Adelstein, MD, FACP, FASCO, Cleveland Clinic, Cleveland [M] Guidelines for HPV-associated Oropharynx - David Adelstein, MD, FACP, FASCO, Cleveland Clinic, Cleveland [M] New Staging and How It Affects (or Could Affect) Therapy - Carole Fakhry, MD, MPH, Johns Hopkins University, Baltimore [S] Challenges in Deintensification of Radiation Therapy for HPV-associated Oropharynx Cancer - Sue Yom, MD, PhD, University of California, San Francisco [R] Challenges in Deintensification of Systemic Therapies for HPV-associated Oropharynx Cancer - Jill Gilbert, MD, FACP, FASCO, Vanderbilt University Medical Center, Nashville, Tennessee [M] HPV: Where do we go next? - Maura Gillison, MD, PhD, MD Anderson Cancer Center, Houston [M] Question and Answers
2:45 p.m. - 3:15 p.m.	Coffee Break
3:15 p.m. - 4:15 p.m.	Tumor Board: Early-stage Disease Moderator: Bhisham Chera, MD, University of North Carolina, Chapel Hill, North Carolina [R] Panelists: Paul Loren Swiecicki, MD, University of Michigan, Ann Arbor, Michigan [M] Shlomo Koyfman, MD, Cleveland Clinic, Cleveland [R] Ellie Maghami, MD, FACS, City of Hope, Duarte, California [S] Christine Glastonbury, MD, University of California, San Francisco [Radiologist] Susan Müller, DMD, Emory University, Atlanta [Pathologist]
4:15 p.m. - 5:15 p.m.	Research Feature and Networking Reception

Friday, February 28, 2020

7:00 a.m. - 5:30 p.m.	Registration
7:00 a.m. - 8:00 a.m.	Continental Breakfast
7:55 a.m. - 8:00 a.m.	Day Two Welcome Cherie-Ann O. Nathan, MD, Louisiana State University Health Sciences Center, Shreveport, Louisiana [S]
8:00 a.m. - 9:30 a.m.	Larynx/Hypopharynx Moderator: Robert I. Haddad, MD, Dana-Farber Cancer Institute, Boston [M] Guidelines for Larynx/Hypopharynx - Sharon Spencer, MD, University of Alabama at Birmingham, Birmingham, Alabama [M] Surgical Approaches for Early Laryngeal Cancer - Brandon Jackson Baird, MD, University of Chicago, Chicago [S] Role of Induction - Francis P. Worden, MD, University of Michigan Health System, Ann Arbor, Michigan [M] Guidelines for Target Delineation - Matthew Witek, MD, MS, University of Wisconsin Hospitals and Clinics, Madison, Wisconsin [R] Questions and Answers
9:30 a.m. - 10:15 a.m.	Keynote II: Immune-related Therapies and Clinical Trial Updates Moderator: Quynh-Thu Le, MD, FASTRO, Stanford University, Stanford, California [R] Panelist: Ezra Cohen, MD, University of California San Diego, La Jolla, California [M] 30 minutes
10:15 a.m. - 10:45 a.m.	Coffee Break
10:45 a.m. - 12:15 p.m.	Oral Abstract Session Moderator: Robert I. Haddad, MD, Dana-Farber Cancer Institute, Boston [M] 10: Long-Term Update of a Phase II Study of Concurrent Chemoradiotherapy Using Radiation + Bevacizumab (BV) For Locally or Regionally Advanced Nasopharyngeal Cancer (NPC): RTOG 0615 - Nancy Y. Lee, MD, FASTRO, Memorial Sloan Kettering Cancer Center, New York 11: A Combination of Three Biomarkers for HNSCC Prognostication Following Chemoradiotherapy - James Rocco, MD, PhD, The Ohio State University, Columbus, Ohio 12: Primary Chemoradiotherapy or Transoral Robotic Surgery for Stage I-II HPV-associated Oropharyngeal Squamous Cell Carcinoma - Ryan Hughes, MD, Wake Forest School of Medicine, Winston Salem, North Carolina 13: Imaging Response Versus Operative Laryngoscopy Assessment of Induction Chemotherapy Response in an Induction Bioselection Approach to Larynx Cancer -Elizabeth Jaworski, MD, University of Michigan, Ann Arbor, Michigan 14: Circulating Tumor Associated Cells in Head and Neck Cancers are Resistance Educated per Previous Chemotherapy Treatments - Timothy Crook, BSc, PhD, MBBS, FRCP, Royal Surrey County Hospital, Guildford, England 15: An Open-label, Non-randomized, Multi-arm, Phase II Trial Evaluating Pembrolizumab Combined with Cetuximab in Patients (pts) with Recurrent/metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Updated Results of Cohort 1 Analysis - Assuntina G. Sacco, MD, University of California San Diego, La Jolla, California 16: Delivering High-quality Head and Neck Low-risk Clinical Target Volumes through a Fully-automated Artificial Intelligence-based Approach - Carlos Cardenas, PhD, MD Anderson Cancer Center, Houston
12:15 p.m. - 1:15 p.m.	Lunch in the Exhibit Hall Trainee and Early-career Networking Luncheon This is an invaluable opportunity for any attendee who is less than three years out of training to speak with and learn from experts in the head and neck cancer care community. Join faculty in an informal setting to discuss topics such as how to build a network outside of your institution, how to establish yourself as a clinical investigator, how to evaluate job opportunities and how to move on after your first job. By attending, you will gain meaningful insight into career paths and development that will help support you in your medical career. Those interested in attending must register for this free, ticketed event. Speakers: Quynh-Thu Le, MD, FASTRO, Stanford University, Stanford, California [R] Maie St. John, MD, PhD, UCLA Medical Center, Los Angeles [S] Francis P. Worden, MD, University of Michigan Health System, Ann Arbor, Michigan [M]
1:15 p.m. - 2:45 p.m.	Rare Cancers of the Head and Neck Moderator: Jonathan J. Beitler, MD, MBA, FACR, FASTRO, Emory University School of Medicine, Atlanta [R] Challenges in Salivary Gland and Sinonasal Neuroendocrine Pathology - Annemieke van Zante, MD, PhD, University of California, San Francisco [Pathologist] Salivary Gland Cancer - Alan L. Ho, MD, PhD, Memorial Sloan Kettering Cancer Center, New York [M] Esthesioneuroblastoma - Jonathan J. Beitler, MD, MBA, FACR, FASTRO, Emory University School of Medicine, Atlanta [R] Sinonasal Neuroendocrine and Undifferentiated Carcinomas - Ehab Y. Hanna, MD, FACS, MD Anderson Cancer Center, Houston [S]
2:45 p.m. - 3:15 p.m.	Coffee Break
3:15 p.m. - 4:30 p.m.	Breakout Session I: Advances in Molecular Imaging Moderator: Eben L. Rosenthal, MD, Stanford University, Stanford, California [S/Radiologist] Intraoperative Molecular Imaging - Eben L. Rosenthal, MD, Stanford University, Stanford, California [S/Radiologist] FDG PET/CT and Head and Neck Cancer - Jian Q. (Michael) Yu, MD, FACNM, FRCPC, Fox Chase Cancer Center, Philadelphia [Radiologist] Potential Theranostic Agents in Head and Neck Cancer - Ana P. Kiess, MD, PhD, Johns Hopkins University, Baltimore [R] Questions and Answers Breakout Session II: Survivorship Moderator: Stuart J. Wong, MD, Medical College of Wisconsin, Milwaukee, Wisconsin [M] Financial Toxicity and Employment in Head and Neck Cancer Patients - Barbara A. Murphy, MD, Vanderbilt University Medical Center, Nashville, Tennessee [M] Vascular Disease in Head and Neck Cancer Survivorship - David M. Brizel, MD, Duke Cancer Center, Durham, North Carolina [R] Are Current PROs Adequate for Head and Neck Cancer Patients? - Jolie Ringash, MD, FRCPC, MSc, University of Toronto, Toronto [R] The Influence of the Oral Microbiome in Head and Neck Cancer Patients - Mark S. Chambers, DMD, MS, MD Anderson Cancer Center, Houston [Oral Oncologist] Questions and Answers
4:30 p.m. - 5:30 p.m.	Tumor Board: Advanced Disease Moderator: David Eisele, MD, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore [S] Panelists: Carol R. Bradford, MD, MS, University of Michigan, Ann Arbor, Michigan [S] Tabby Kennedy, MD, University of Wisconsin, Madison, Wisconsin [Radiologist] Susan Müller, DMD, Emory University, Atlanta [Pathologist] Brian O'Sullivan, MD, FASTRO, Princess Margaret Hospital, Toronto [R] David G. Pfister, MD, Memorial Sloan Kettering Cancer Center, New York [M]

Saturday, February 29, 2020

7:00 a.m. - 12:15 p.m.	Registration
7:00 a.m. - 8:00 a.m.	Continental Breakfast
7:55 a.m. - 8:00 a.m.	Welcome
8:00 a.m. - 9:30 a.m.	Advances in Immunotherapy Moderator: Robert L. Ferris, MD, PhD, University of Pittsburgh Medical Center, Pittsburgh [S] Established and Emerging Biomarkers for Immunotherapy - Nadeem Riaz, MD, MSc, Memorial Sloan Kettering Cancer Center, New York [R] Combination Immunotherapy - Charu Aggarwal, MD, MPH, University of Pennsylvania, Philadelphia [M] Role of Immunotherapy in Curative Intent - Barbara Burtness, MD, Yale Cancer Center, New Haven, Connecticut [M] Cellular Therapy - Christian S. Hinrichs, MD, National Cancer Institute, Bethesda, Maryland [S/M] Questions and Answers
9:30 a.m. - 10:15 a.m.	De-escalation Debate Moderator: Cherie-Ann O. Nathan, MD, Louisiana State University Health Sciences Center, Shreveport, Louisiana [S] For De-escalation - Robert L. Ferris, MD, PhD, University of Pittsburgh Medical Center, Pittsburgh [S] Against De-escalation - Maura Gillison, MD, PhD, MD Anderson Cancer Center, Houston [M] Questions and Answers
10:15 a.m. - 10:45 a.m.	Coffee Break
10:45 a.m. - 12:15 p.m.	Cutaneous Squamous Cell Carcinoma and Carcinoma of Unknown Primary Moderator: Carole Fakhry, MD, MPH, Johns Hopkins University, Baltimore [S] Guidelines for Unknown Primary Management - Jimmy J. Caudell, MD, PhD, Moffitt Cancer Center, Tampa, Florida [R] Pathology for Unknown Primary and How to Grade Perineural Invasion for Skin Cancer - Annemieke van Zante, MD, PhD, University of California, San Francisco [Pathologist] Radiation Oncology for Skin Cancer - Richard Bakst, MD, Mount Sinai Hospital, New York [R] Systemic Treatment of Skin Cancer - Danny Rischin, MD, MBBS, FRACP, Peter MacCallum Cancer Centre, Melbourne, Australia [M] Questions and Answers